Sodium nitrite inhalation - Aires Pharmaceuticals

Drug Profile

Sodium nitrite inhalation - Aires Pharmaceuticals

Alternative Names: AIR-001; Aironite

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator National Heart, Lung and Blood Institute
  • Developer Aires Pharmaceuticals; Mayo Clinic
  • Class Antidotes; Antihypertensives; Nitrites; Small molecules; Sodium compounds; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure; Pulmonary arterial hypertension

Most Recent Events

  • 03 Nov 2016 Interim efficacy adverse events data from a institution-sponsored phase II trial in Pulmonary arterial hypertension released by Mast Therapeutics
  • 01 Sep 2016 Mayo Clinic in collaboration with Aires Pharmaceuticals, Mast Therapeutics and National Heart, Lung, and Blood Institute initiates enrolment in a phase II trial for Heart Failure in USA (NCT02713126)
  • 01 Aug 2016 Mast Therapeutics initiates enrolment in the INDIE-HFpEF trial for Heart failure in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top